Products Categories
  • Mr.Mr. Eddie Dong
    Tel: 86-0519-86879655

  • Ms.Bessie
    Tel: 18061870631

  • Ms.Haylee
    Tel: 18061870061

  • Mobile:
  • Tel:86-0519-86879655
  • Fax:
  • URL:https://eubo.en.alibaba.com
  • Province/state:
  • City:
  • Street:No. 18, Huashan Road, Xinbei District, Changzhou, Jiangsu, China (Mainland)
  • MaxCard:
Home > Products >  Manufacture Raw Material CAS 850649-62-6 Alogliptin Benzoate

Manufacture Raw Material CAS 850649-62-6 Alogliptin Benzoate CAS NO.850649-62-6

  • Min.Order: 0
  • Payment Terms:
  • Product Details

Keywords

  • Alogliptin benzoate
  • Alogliptin Benzoate Raw Material
  • 850649-62-6

Quick Details

  • ProName: Manufacture Raw Material CAS 850649-62...
  • CasNo: 850649-62-6
  • Molecular Formula: C25H27N5O4
  • Appearance: White to off-white powder
  • Application: Antidiabetics (DPP4 Inhibitor)
  • DeliveryTime: Abiut 10 days
  • PackAge: Aluminum foil bag,fluorinated bottles,...
  • Port: Shenzhen port
  • Purity: 99%
  • Storage: Store in cool & dry place. Keep away f...
  • Transportation: 1) Door to Door Service by DHL/FEDEX/E...
  • LimitNum: 0
  • Moisture Content: <0.1%
  • Impurity: <0.1%

Superiority

1) Provide costomers with "one-stop"packaging service,from research,development,production,export and so on.
2) We have our own R&D and production base,equipped with advanced production equipment and precision testing the Unitef States Pharmacopoeia(USP),the Britis Pharmacopoeia(EP) and other international advanced standards.All products are through the KOSGER,HALAL certification,the ISO quality management system certification and the HACCP certification.
3) More than 12 years of export experience.
4)Competitive price in China market.

Details

Alogliptin benzoate is a serine protease two peptide peptidase IV (DPP- IV) inhibitor developed by Takeda company in japan. This product can maintain the levels of glucagon like peptide 1 (GLP-1) and Glucose dependent insulin-like growth polypeptide (GIP) in vivo and promote the secretion of insulin and thus exert hypoglycemic effect. A randomized, placebo-controlled clinical trial results showed that, compared with placebo Agger gliptin monotherapy can significantly improve glycemic control in type 2 diabetes, did not increase the incidence of hypoglycemia, well tolerated. A Glenn Dean and the medicine composition is the sitagliptin, vildagliptin asked the city after oral administration of effective specific DPP- IV inhibitors, provides a new choice of treatment for patients with type 2 diabetes, and has wide application prospect.

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog